Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987193 | 0.91 | PIK3CA (0.42) | PIK3CABRD4CREBBPAKT1MTOR | |
| SCHEMBL1987756 | 0.89 | MCHR1 (0.39) | MCHR1 | |
| SCHEMBL1987279 | 0.86 | SIGMAR1 (0.52) | PIK3CABRD4CREBBPSIGMAR1PDGFRB | |
| SCHEMBL1986131 | 0.80 | MGLL (0.37) | — | |
| SCHEMBL1987185 | 0.75 | SIGMAR1 (0.49) | MCHR1BRD4CREBBPHSP90AA1SIGMAR1 | |
| SCHEMBL1985449 | 0.71 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL1990165 | 0.67 | PDGFRB (0.42) | PIK3CABRD4CREBBPHSP90AA1PDGFRB | |
| SCHEMBL27833818 | 0.66 | PDGFRB (0.60) | BRD4CREBBPPDGFRBPDGFRA | |
| SCHEMBL1987079 | 0.64 | SIGMAR1 (0.57) | MCHR1SIGMAR1 | |
| SCHEMBL1988736 | 0.63 | SIGMAR1 (0.42) | MCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | INMT, IDO1, IDO2 | PIK3CA 2938/4885MCHR1 591/4885BRD4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.